Pharmacokinetic Analysis of Nicotinamide Riboside

Early Phase 1

Completed

• Conditions: Healthy Participants
• Interventions: Dietary Supplement: Nicotinamide riboside

• Registration Number: NCT02300740
• Lead Sponsor: Aarhus University Hospital

Brief Summary

Nicotinamide riboside is a newly discovered vitamin B3. The pharmacokinetics in humans is so far not analyzed.

Detailed Description

Not available

Study Timeline

• Status Verified: 2014-11
• Study First Submitted: 2014-11-20
• Study First Submitted QC: 2014-11-21
• Study First Posted: 2014-11-25
• Study Start: 2014-12
• Primary Completion: 2015-02
• Last Update Submitted: 2015-02-26
• Last Update Posted: 2015-02-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 12

Inclusion Criteria

• BMI 18-25, healthy, male,

Exclusion Criteria

• liver or kidney diseases, other diseases

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
low dose	Nicotinamide riboside	500 mg nicotinamide riboside oral
high dose	Nicotinamide riboside	1000 mg nicotinamide riboside oral

Primary Outcome Measures

Name	Time	Method
Serum nicotinamide riboside	8 hours, blood samples every 15 min

Secondary Outcome Measures

Name	Time	Method
serum concentrations of metabolites of nicotinamide riboside	8 hour, blood samples every 15 min
area under the curve for serum nicotinamide riboside	8 hours, blood samples every 15 min
calculation of halftime of serum nicotinamide riboside	8 hours, blood samples every 15 min
calculation of C-max of serum nicotinamide riboside	8 hours, blood samples every 15 min
calculation of t-max of serum nicotinamide riboside	8 hours, blood samples every 15 min

Trial Locations

Locations (1)

Medical Research Laboratories, Aarhus University Hospital; 🇩🇰 Aarhus, Denmark